Abstract:Tularemia is a zoonosis caused by the Gram negative, facultative intracellular bacterium Francisella tularensis . This disease has multiple clinical presentations according to the route of infection, the virulence of the infecting bacterial strain, and the underlying medical condition of infected persons. Systemic infections (e.g., pneumonic and typhoidal form) and complications are rare but may be life threatening. Most people suffer from local infection (e.g., skin ulcer, conjunctivitis, or pharyngitis) with regional lymphadenopathy, which evolve to suppuration in about 30% of patients and a chronic course of infection. Current treatment recommendations have been established to manage acute infections in the context of a biological threat and do not consider the great variability of clinical situations. This review summarizes literature data on antibiotic efficacy against F. tularensis in vitro , in animal models, and in humans. Empirical treatment with beta-lactams, most macrolides, or anti-tuberculosis agents is usually ineffective. The aminoglycosides gentamicin and streptomycin remain the gold standard for severe infections, and the fluoroquinolones and doxycycline for infections of mild severity, although current data indicate the former are usually more effective. However, the antibiotic treatments reported in the literature are highly variable in their composition and duration depending on the clinical manifestations, the age and health status of the patient, the presence of complications, and the evolution of the disease. Many patients received several antibiotics in combination or successively. Whatever the antibiotic treatment administered, variable but high rates of treatment failures and relapses are still observed, especially in patients treated more then 2–3 weeks after disease onset. In these patients, surgical treatment is often necessary for cure, including drainage or removal of suppurative lymph nodes or other infectious foci. It is currently difficult to establish therapeutic recommendations, particularly due to lack of comparative randomized studies. However, we have attempted to summarize current knowledge through proposals for improving tularemia treatment which will have to be discussed by a group of experts. A major factor in improving the prognosis of patients with tularemia is the early administration of appropriate treatment, which requires better medical knowledge and diagnostic strategy of this disease.

Tularemia: A Storied History, An Ongoing Threat

Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023

Tularemia From Veterinary Occupational Exposure

Tularemia treatment: experimental and clinical data

Current vaccine strategies and novel approaches to combatting Francisella infection

Francisella tularensis Bone and Joint Infections: United States, 2004–2023

Non-vaccinal prophylaxis of tularemia

Tularemia Clinical Manifestations, Antimicrobial Treatment, and Outcomes: An Analysis of US Surveillance Data, 2006–2021

Neuroinvasive Francisella tularensis Infection: Report of 2 Cases and Review of the Literature

Confirmed Case of Longstanding Respiratory Francisella tularensis holarctica Infection: Nebraska, 2022

Tularemia on the rise in Switzerland? A one health approach is needed!

Ulceroglandular tularemia

Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes from an 11-year Retrospective Observational Cohort in Northern Sweden

[A rare and atypical form of tularemia in a context of immunodepression]

Rare Case of Tularemia With Preauricular Lymphadenopathy and Conjunctivitis in a 27-Year-Old Male Patient in Germany

Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009–2018

Tularemia: a case series from an endemic area in Hajnówka County, Norteast Poland

Tularämie (Hasenpest)

Evolution of Antibiotic Resistance in Surrogates of Francisella tularensis (LVS and Francisella novicida): Effects on Biofilm Formation and Fitness

Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 ΔclpB, to Prevent Tularemia

A case of pulmonary tularemia mimicking lung cancer